Nutriband Inc.Abuse-deterrent fentanyl patch • FDA 505(b)(2) pathway • Revenue-generating manufacturing base
6 Reasons NTRB Is On Our Watchlist
Nutriband is developing AVERSA Fentanyl, an abuse-deterrent transdermal fentanyl patch, on the FDA's 505(b)(2) pathway with Kindeva Drug Delivery, while its subsidiaries manufacture transdermal products and sell consumer wellness tapes.
The company completed an FDA meeting on chemistry, manufacturing and controls, received the final meeting minutes, and said it is incorporating that feedback as it moves toward an IND filing in support of a Human Abuse Potential study — the study its NDA is expected to be built around.
The next regulatory step for AVERSA Fentanyl: an IND filing supporting a Human Abuse Potential study. The company has not announced an IND clearance, a study start, or an NDA submission date.
What stands out is a single, clearly defined lead asset in a category with a real public-health problem, paired with an existing manufacturing base and a balance sheet the company says no longer carries substantial doubt about its ability to continue as a going concern.
Nutriband Inc. (NASDAQ: NTRB) is a specialty pharmaceutical company headquartered in Orlando, Florida, with a January 31 fiscal year end. It develops transdermal (skin patch) pharmaceutical products and owns manufacturing and consumer-product subsidiaries.
Its lead development asset is AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl patch that incorporates the company's AVERSA abuse-deterrent technology. Alongside it, the company manufactures transdermal and topical products for third parties and sells its own AI Wellness kinesiology and sports tape lines.
Contract manufacturing customers for its Pocono operation, retail and distribution partners for the consumer tape lines, and — if AVERSA Fentanyl is ultimately approved — the prescription pain-management market served through pharmaceutical distribution channels.
Current revenue comes from contract manufacturing and consumer product sales. Any pharmaceutical revenue from AVERSA Fentanyl would depend on completing development and obtaining FDA approval, which has not happened.
Corporate offices in Orlando, Florida, with manufacturing through Pocono Pharmaceutical / Pocono Coated Products, transdermal development through 4P Therapeutics, and consumer products through Active Intelligence. AVERSA Fentanyl CMC and manufacturing work is being carried out in partnership with Kindeva Drug Delivery.
Nutriband is a clinical-stage developer with a small revenue base. For the fiscal year ended January 31, 2026 it reported revenue of $2.04 million and a net loss of $8.23 million, with $4.57 million of cash at year end. AVERSA Fentanyl has not been approved and no NDA has been publicly announced as filed.
The points below draw on the company's public disclosures, its recent operational updates, and TopStocks commentary. We distinguish between confirmed facts, company statements, and our own editorial framing.
AVERSA™ Fentanyl is a transdermal fentanyl patch built around Nutriband's abuse-deterrent technology. Transdermal fentanyl is a legitimate and widely prescribed analgesic that is also a known target for misuse, and Nutriband's pitch is a patch that keeps the therapeutic profile while making abuse harder. On March 30, 2026 the company announced it had selected the commercial brand name for the product — the kind of step a company takes when it is thinking about commercialization rather than early science.
The program is being pursued under the FDA's 505(b)(2) pathway, which lets a sponsor rely in part on existing findings of safety and efficacy for an already-approved drug. Nutriband has said the NDA is expected to be based primarily on a single Phase 1 Human Abuse Potential study rather than a full Phase 2/3 program. That is a materially shorter and cheaper path than a novel molecule — but it is still an FDA review with no guaranteed outcome, and no NDA submission date has been announced.
On October 28, 2025 the company announced it had completed a meeting with the FDA covering chemistry, manufacturing and controls for the abuse-deterrent fentanyl patch, received the final meeting minutes, and was incorporating that feedback as it moved toward an IND filing in support of the Human Abuse Potential study. Regulatory dialogue of this kind reduces the odds of a surprise later, though it is not approval and does not guarantee timing.
CMC and manufacturing work on AVERSA Fentanyl is being done with Kindeva Drug Delivery, an established transdermal and inhalation CDMO. Separately, Nutriband owns its own capability: Pocono Pharmaceutical / Pocono Coated Products for contract manufacturing of transdermal and topical products, and 4P Therapeutics for transdermal development. In February 2026 the board terminated an agreement to sell Pocono Pharmaceuticals after the buyer failed to close, so that capacity stayed in-house.
The Active Intelligence / AI Wellness line of kinesiology and sports tapes produces actual sales while the drug program advances. On March 18, 2026 the company said its AI Kinesiology tapes had been approved for distribution and sale in Costa Rica, following a February 17, 2026 exclusive distribution agreement with Innomedica CCB S.A. covering the tape products and — upon any approval — AVERSA Fentanyl. On May 15, 2026 it showcased an expanding wellness portfolio and new product launches at the ECRM conference. Fiscal 2026 revenue was $2.04 million, so this is a supporting business, not the thesis.
Nutriband reported 12,155,983 common shares outstanding as of June 11, 2026. A smaller share count can contribute to greater price sensitivity when trading activity increases.
In a long-form interview shared by the company on April 22, 2026, CEO Gareth Sheridan walks through the scale of the U.S. fentanyl problem, the capsaicin-based abuse-deterrent approach behind AVERSA, and where the business stands today.
Read the company's announcement of the episode.
The interview is company-provided commentary and contains forward-looking statements. It is not an independent verification of the company's plans or technology, and nothing in it is investment advice.
The following points are drawn from Nutriband's own press releases and its filings with the SEC, reproduced here as the company reported them.
AVERSA™ Fentanyl, an abuse-deterrent transdermal fentanyl patch, is in development under the FDA's 505(b)(2) pathway.
A meeting with the FDA on chemistry, manufacturing and controls was completed and final minutes received, per the company's October 28, 2025 announcement.
The company said it is incorporating FDA feedback as it moves toward an IND filing in support of a Human Abuse Potential study.
A commercial brand name for the abuse-deterrent fentanyl patch was announced on March 30, 2026.
Kindeva Drug Delivery, an established transdermal CDMO, works with Nutriband on CMC and manufacturing for the program.
AI Kinesiology tapes were approved for distribution and sale in Costa Rica on March 18, 2026 under the Innomedica agreement.
Cash and cash equivalents of $4,006,184 at April 30, 2026, plus an amended three-year $5 million credit facility disclosed June 22, 2026.
AVERSA Fentanyl is an investigational product that has not been approved by the FDA. No IND clearance, Human Abuse Potential study start, or NDA submission has been publicly announced, and there is no assurance the product will be approved or commercialized. Nutriband is unprofitable and reported a net loss of $8,229,632 for the fiscal year ended January 31, 2026. Investors should confirm all figures against the company's filings with the SEC before making any investment decision.
Nutriband pairs a single, clearly defined pharmaceutical development program with manufacturing, development and consumer-product subsidiaries that already produce revenue — a rare structure for a company of this size.
An abuse-deterrent transdermal fentanyl patch built on the company's AVERSA technology, developed with Kindeva Drug Delivery. Following a completed FDA meeting on chemistry, manufacturing and controls, the company said it is working toward an IND filing in support of a Human Abuse Potential study. A commercial brand name was announced on March 30, 2026.
No IND clearance, study start, or NDA submission has been publicly announced. FDA approval is not assured.
The company's transdermal and topical contract manufacturing operation, also known as Pocono Coated Products. In an 8-K filed February 13, 2026 the board disclosed it had terminated the agreement to sell Pocono Pharmaceuticals to Earth Vision Bio Inc. after the buyer failed to close, keeping the capacity in-house.
The terminated sale also means the expected proceeds were not received, which matters for a company with a modest cash balance.
The wholly owned development subsidiary behind Nutriband's transdermal product work, providing in-house formulation and development capability alongside the Kindeva partnership on the lead program.
Development capability does not shorten the FDA review path or guarantee a successful outcome.
The consumer kinesiology and sports tape lines that generate the company's current sales. AI Kinesiology tapes were approved for distribution and sale in Costa Rica on March 18, 2026, following the February 17, 2026 exclusive agreement with Innomedica CCB S.A., and an expanded portfolio was showcased at ECRM in May 2026.
Total company revenue for the year ended January 31, 2026, against $2,139,537 the prior year. Quarterly revenue declined year over year in Q1 FY2027.
Regulatory plans and distribution agreements described above are forward-looking statements made by the company and are not guarantees of approval, future orders, revenue or profitability. Actual results may differ materially. Read the company's SEC filings.
The company announced that CEO Gareth Sheridan would present as part of the CEO Spotlight at the 2026 Georgia Life Sciences Summit, held August 25–26, 2026.
In an 8-K filed June 22, 2026, the company disclosed an amended three-year $5,000,000 credit facility bearing 7% interest, replacing a prior facility dated March 19, 2023 that was set to expire July 13, 2026.
For the quarter ended April 30, 2026 Nutriband reported revenue of $433,399 against $667,432 a year earlier, a net loss of $1,241,956 versus $1,388,869, loss per share of $(0.10), and cash and cash equivalents of $4,006,184. The cover page listed 12,155,983 common shares outstanding.
The company said it would present its growing AI Wellness consumer portfolio, including new product launches slated for June, at the ECRM conference.
For the fiscal year ended January 31, 2026 the company reported revenue of $2,036,651, cost of revenue of $1,470,343, gross profit of $566,308, a net loss of $8,229,632, and cash and cash equivalents of $4,574,857 with working capital of $4,204,632. Net loss available to common stockholders was $(30,043,798), or $(2.58) per share, after preferred dividends. Management stated that substantial doubt about the company's ability to continue as a going concern is alleviated.
The company shared a long-form interview in which CEO Gareth Sheridan discusses the U.S. fentanyl crisis, the capsaicin-based abuse-deterrent approach behind AVERSA, and a general update on the business.
The company announced it had selected the commercial brand name for its abuse-deterrent transdermal fentanyl patch, a step tied to eventual commercialization planning. The release was furnished to the SEC on an 8-K filed April 7, 2026.
Regulatory clearance was granted for the company's AI Kinesiology tape products to be distributed and sold in Costa Rica, following the February 17, 2026 exclusive distribution agreement with Innomedica CCB S.A.
The agreement gives Innomedica CCB S.A. exclusive Costa Rican distribution rights to the company's kinesiology and sports tape lines, mosquito-repellent patches, and AVERSA Fentanyl upon any regulatory approval.
In an 8-K filed February 13, 2026, the company disclosed that its board terminated the agreement to sell Pocono Pharmaceuticals to Earth Vision Bio Inc. after the buyer failed to pay late fees and close by December 31, 2025.
The company said it completed a meeting with the FDA on chemistry, manufacturing and controls, received the final meeting minutes, and was incorporating the feedback as it moves toward an IND filing in support of a Human Abuse Potential study.
Upcoming events retail investors are monitoring for NTRB. None of these outcomes are guaranteed.
Following the completed FDA CMC meeting and receipt of final minutes, the company has said it is working toward an IND filing in support of a Human Abuse Potential study for AVERSA Fentanyl.
Rollout of the AI Wellness kinesiology and sports tape lines through retail channels and the Innomedica agreement in Costa Rica, plus the new product launches showcased at ECRM in May 2026.
The quarter ended July 31, 2026 had not been filed as of early September 2026. The next report will show revenue trend, cash burn against the $4.0 million balance reported at April 30, 2026, and any use of the amended $5 million credit facility.
Potential catalysts may be delayed, changed, unsuccessful, or already reflected in the stock's market price.
A single, well-defined lead asset on the 505(b)(2) pathway, an FDA meeting completed with minutes in hand, an established transdermal partner in Kindeva, in-house manufacturing, a consumer line already producing sales, and roughly 12.2 million shares outstanding — Nutriband is an unusually concentrated story for a company this small.
None of that makes AVERSA Fentanyl approved. There is no announced IND clearance, no study start, and no NDA date, and the company lost $8.2 million in its last fiscal year against about $4 million of cash. But the path is narrow and clearly stated, and NTRB stays on our radar heading into the next regulatory update.
This is sponsored editorial content, not investment advice. Share price and market capitalization figures are approximate and should be verified against a live Nasdaq quote. See the full disclosure below before making any investment decision.
Live quote.
Live quote.
Revenue of $2,036,651 for the fiscal year ended January 31, 2026, against $2,139,537 the prior year, as reported in the company's annual report on Form 10-K.
Net loss of $8,229,632 for the fiscal year ended January 31, 2026, versus $10,482,617 the prior year. Net loss available to common stockholders was $(30,043,798), or $(2.58) per share, after preferred dividends.
Revenue of $433,399 for the quarter ended April 30, 2026, compared with $667,432 in the prior-year quarter, with a net loss of $1,241,956 and loss per share of $(0.10).
Cash and cash equivalents of $4,006,184 at April 30, 2026, down from $4,574,857 at January 31, 2026. An amended three-year $5 million credit facility at 7% interest was disclosed on June 22, 2026.
Financial figures should be verified against the company's latest SEC filings. Historical performance does not guarantee future results.
Look up Nutriband Inc. (NASDAQ: NTRB) on your preferred trading platform to review real-time quotes, charts, and filings.
Brokerage names and logos are trademarks of their respective owners. TopStocks is not affiliated with or endorsed by any of the listed brokerages.
Live data via TradingView · NASDAQ:NTRB
Chart provided by TradingView. Displayed for informational purposes only. No support levels, price targets, or technical predictions are shown or implied by TopStocks.
MASTER LEGAL DISCLAIMER
Last Updated: Sep 07, 2026
Publisher: Relqo Media LLC (Wyoming, United States)
Subject Company: Nutriband Inc. (NTRB)
IMPORTANT SUMMARY, PLEASE READ FIRST
This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash to produce and distribute promotional content regarding Nutriband Inc. (NASDAQ: NTRB). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker dealer, investment adviser, or securities analyst. Investing in small cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.
1. NATURE AND INTENT OF THIS COMMUNICATION
Relqo Media LLC is a for profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These communications are not intended to be factual evaluations of the company's operations or investment merit.
2. COMPENSATION FOR Nutriband Inc. (NTRB)
Relqo Media LLC has been engaged by Penzance LLC to provide investor awareness and promotional media services for Nutriband Inc. (NASDAQ: NTRB).
3. INTENDED AUDIENCE
These communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and NASDAQ listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These communications are not intended to guide investment for long-term portfolio management or financial planning purposes.
4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS
Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.
Any and all information regarding Nutriband Inc. (NASDAQ: NTRB), including but not limited to business descriptions, operating updates, acquisitions, revenue projections, financing arrangements, partnerships, inventory growth, expansion plans, or strategic plans, should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.
We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.
You should not rely on any company provided claims, projections, or forward looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.
If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence, including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts, before making any investment decision.
5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION
Historically, promotional campaigns for microcap and small-cap securities, particularly those driven by paid advertising, often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.
You should assume and expect that:
Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.
By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.
6. NO RELIANCE, INVESTOR RESPONSIBILITY
The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.
You are solely responsible for:
We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company's business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.
By viewing our materials, you agree that:
7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE
Our materials may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as predictive or aspirational language regarding future events, performance, or results. Words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will," "should," "could," "projects," "estimates," "potential," and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in market conditions, financing availability, integration risks, consumer demand, competitive pressures, and broader economic or geopolitical developments.
Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated.
You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.
8. INFORMATION SOURCING, BIAS, AND ACCURACY
We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.
Assume all information presented by Relqo Media is:
9. OWNERSHIP AND TRADING CONFLICTS
Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including NTRB. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.
10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT
We use a range of outreach and promotional tools, including:
By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.
11. ADVERTISING LAW COMPLIANCE
Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC's interpretations of sponsored investment-related communications.
We make good-faith efforts to disclose all:
We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.
12. NON-U.S. USERS
This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country's laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.
13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY
All content is provided as is and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:
Total liability for any claim shall not exceed one hundred dollars ($100).
14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION
All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.
15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS
Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.
16. FINAL NOTICE, ACCEPTANCE OF TERMS
We reserve the right to update this disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.
If you do not accept all terms of this disclaimer in full, you must:
17. NO RELIANCE
By viewing or engaging with this content, you agree that:
© 2024 Relqo Media LLC. All Rights Reserved.
Legal Contact: support@topstocks.com
Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801
Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.
